---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-022574"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:04:59.775578+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NAVIGATE trial: belapectin 2mg significantly reduces new varices in MASH cirrhosis patients

## Summary
- In per-protocol, belapectin 2mg reduced new varices incidence at 18 months (p=0.04) vs placebo.
- Liver stiffness measure improved -12.3% mean change for belapectin 2mg vs -3.1% for placebo.
- Fewer subjects on belapectin showed worsening LSM >30% or >10 kPa (p=0.03 for 2mg, p=0.02 for 4mg).
- Safety profile comparable to placebo: no drug-related SAEs, no DILI, similar discontinuation rates.
- U.S. subgroup showed significant varices reduction with belapectin 2mg (p=0.02).

## SEC filing metadata
- accession: 0001140361-25-022574
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125022574/0001140361-25-022574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125022574/ef20050576_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-022574
- JSON: https://secwatch.observer/filing/0001140361-25-022574.json
- Plain text: https://secwatch.observer/filing/0001140361-25-022574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.